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Abstract
Objective: In order to expand the use of photodynamic
therapy (PDT) in the treatment of prostate carcinoma
(PCA), the aim of this study was to evaluate PDT by
means of 5-aminolevulinic acid (5-ALA)-induced proto-
porphyrin IX (PPIX) in an in vivo tumor model. Methods:
The model used was the Dunning R3327 tumor. First of
all, the pharmacokinetics and the localization of PPIX
were obtained using fluorescence measurement tech-
niques. Thereafter, PDT using 150 mg 5-ALA/kg b.w. i.v.
was performed by homogenous irradiation of the photo-
sensitized tumor (diode laser Ï = 633 nm). The tumors
were resected 2 days post-PDT and the extent of the
necrosis was determined histopathologically. Results:
The kinetics of PPIX fluorescence revealed a maximum
intensity in the tumor tissue within 3 and 4.5 h post-appli-
cation of 5-ALA. At this time, specific PPIX fluorescence
could be localized selectively in the tumor cells. The PDT-
induced necrosis (n = 18) was determined to be 94 B
12% (range 60–100%), while the necrosis of the controls
(n = 12) differs significantly (p ! 0.01), being less than
10%. Conclusion: These first in vivo results demonstrate
the effective potential of 5-ALA-mediated PDT on PCA in
an animal model.
Copyright © 2004 S. Karger AG, Basel
Introduction
Radical prostatectomy, external beam radiation and
brachytherapy are considered to be the main treatment
modalities in localized prostate cancer (PCA). However,
severe bleeding, incontinence and impotence are consid-
ered to be the main side effects, especially in open surgery
[1, 2]. Therefore, efforts have been made to establish min-
imal invasive treatment modalities of PCA, like high-
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intensity focused ultrasound or cryosurgical ablation [3,
4]. In addition, photodynamic therapy (PDT) has been
proposed as a promising in situ treatment for localized
PCA [5]. PDT is a technique using the interaction be-
tween an administered photosensitizing agent serving as a
transient accumulation in cancerous tissue and light with
an appropriate wavelength which is then absorbed by the
photosensitizer. Consequently, this light-induced photo-
chemical process causes a selective tissue necrosis. Re-
cently, the effectiveness of several photodynamic agents
in PDT on PCA was investigated in a number of experi-
mental studies [6–8]. However, there was a major draw-
back because of the skin photosensitization caused by the
most commonly used agents, for instance hematoporphy-
rin derivative (HPD) [9]. Therefore, a new generation of
photosensitizers, which causes less skin reactions, is cur-
rently under intensive investigation in the treatment of a
range of malignancies [10]. 5-Aminolevulinic acid (5-
ALA) is a precursor in the heme biosynthesis pathway.
After undergoing a series of enzymatic catalyzed reac-
tions, 5-ALA is metabolized to fluorescent protoporphy-
rin IX (PPIX), before being converted to photo-inactive
heme. PPIX is the endogenous photosensitizer needed for
the PDT, which accumulates temporarily in the tumor tis-
sue after the exogenous application of 5-ALA [11].
Referring to this, there is lack of investigating the 5-
ALA-mediated PDT on an in vivo PCA model which is a
prerequisite to motivate PDT of PCA into clinical trials.
Therefore, the principal objective was to prove the se-
lective tumor-destroying effect of 5-ALA-mediated PDT
in an in vivo prostate tumor, using the R3327 Dunning-
Tumor model.
Materials and Methods
In vivo Tumor Model
The Dunning R3327 tumor was used as prostate tumor model
[12]. Following standard cultivation of the tumor cell subline MatLy-
Lu, 1 W105 cells were injected subcutaneously into the right upper
thigh of anesthetized 2-month-old male Copenhagen rats (b.w. 200–
250 g; Charles River, Sulzfeld, Germany) [13].
The fluorescence measurements as well as the photodynamic
therapies were performed when the tumors reached a size of approxi-
mately 5 mm in diameter (measured with calipers). In all experi-
ments, the skin covering the tumor was removed and the bare tumor
surface was exposed for measurement and illumination. In order to
avoid uncontrolled light exposure (inducing side effects or photo
bleaching), all experiments and preparations were performed in a
darkened room.
The animals were anesthetized by a mask slipped over the nose
for inhalation of a narcotic mixture containing isoflurane and oxygen
(conc.: 1.5–2.5 vol% isoflurane; flowing rate: 0.5 l/min; inhalation
device: Titus with isoflurane Vaporisator 19.3; Dräger Medizintech-
nik, Lübeck, Germany). Before and after treatment, animals received
food and water ad libitum. All experiments were approved by the
appropriate institutional committee as well as by an external animal
protection committee of the government.
5-Aminolevulinic Acid
5-ALA (medac GmbH, Wedel, Germany) was dissolved in 5.7%
sodium monohydrogen phosphate. A solution of 150 mg/kg b.w. of
5-ALA was applied intravenously by means of a cannula inserted
into the right vena femoralis of the hosts.
Fluorescence Measurements
In order to evaluate the efficacy of a 5-ALA-mediated PDT, it is
an indispensable prerequisite to get a secure time range for PDT and
the verification of the selective accumulation of PPIX within the
tumor cells. Therefore, both the pharmacokinetic and localization of
5-ALA-induced PPIX was examined prior to PDT.
PPIX fluorescence was excited by an incoherent light source
emitting light in the spectral range of Ï = 385–440 nm (Karl Storz
GmbH, Tuttlingen, Germany) [14]. The excitation light was guided
by a flexible transmission system to a conventional rigid cystoscope
positioned in front of the bare tumor surface to illuminate a spot size
of 2–3 mm in diameter. The fluorescence light was guided through
the telescope optic of the cystoscope. An optical beam splitter cover-
ing the ocular reflected the fluorescence light, which was then cou-
pled into a flexible fiber for transfer to an optical multichannel ana-
lyzer system (SI-Spectroscopy & Imaging GmbH, Germany). Fluo-
rescence emission spectra were recorded in the spectral range be-
tween Ï = 500 and 750 nm.
In such a way, PPIX fluorescence spectra were obtained from the
MatLyLu tumors of 7 animals. The spectra were taken at intervals of
15–30 min up to a period of 8 h after application of 5-ALA. Imme-
diately before injection of 5-ALA, the background spectrum of the
tumor tissue intrinsic fluorochromes was obtained.
To calculate the PPIX fluorescence kinetics, the spectra of each
tumor were normalized due to their fluorescence intensity at Ï =
605 nm, where no PPIX emission occurs. After subtraction of the
background intensity, the fluorescence intensity of the main PPIX
emission band at Ï = 635 nm was plotted as a function of the time
post-injection for each tumor.
The examination of the localization of the PPIX fluorescence was
performed on an additional three tumors, which were harvested at
the time of maximum PPIX fluorescence due to the fluorescence
kinetic results and prepared for frozen sections. The frozen slides
were examined using fluorescence microscopic techniques and the
adjacent slides were HE-stained to correlate the fluorescence distri-
bution pattern with the histopathology using conventional light
microscopy.
Photodynamic Therapy
PDT was performed by a diode laser (CeraLas PDT 633,
CeramOptec GmbH, Bonn, Germany) emitting at a wavelength of
Ï = 633 nm. The light was transmitted via a flexible micro lens ended
fiber to the target tissue. In such way a homogenous light intensity
distribution on an area of 1.5 cm2 covering the tumor tissue and
a border of about 5 mm was obtained. The irradiance was set to
100 mW/cm² and measured immediately before and after each illu-
mination by means of a calibrated power meter. To obtain an irradia-
tion of 100 J/cm2, each tumor was illuminated for 1,000 s.
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Fig. 1. PPIX fluorescence kinetic of the
main PPIX fluorescence emission band at
Ï = 635 nm of a single Dunning R3327
tumor (insert: PPIX fluorescence spectrum).
According to the accumulation time derived from the PPIX fluo-
rescence kinetics measurements, PDT was performed on 18 animals
(group IV). The size of the bare tumor was measured with a caliper
immediately before photodynamic irradiation.
The tumors were harvested 48 h post-PDT and again their sizes
were measured using calipers. Afterwards the tumors were prepared
in serial sections for HE staining to determine the size of necrotic
area histopathologically.
The tumor sections were inspected and the diameter of the total
tumor area as well as the tumor necrotic sector were both measured
in two perpendicular dimensions by means of an intraocular caliper
of the light microscope (magnification !40). The size of the areas
were calculated, assuming an elliptical shape according to the ellipse
formula (A = a Wb W). The percentage of necrosis for each individual
tumor was calculated by the ratio of necrotic area divided by the total
tumor area.
Twelve animals, bearing the Dunning R3327 tumor at the same
location as the 18 PDT-treated animals, served as controls. After
undergoing identical preparations they received the following treat-
ment: (group I) neither 5-ALA nor light, (group II) only 5-ALA no
light, (group III) only light no 5-ALA. After 2 days the tumor tissue
was harvested and the histological examination followed according
to the PDT-treated animals (group IV).
Statistical Analysis
Average, standard deviation and the range of the percentage of
necrotic areas were calculated using standard software (MS-Excel
2000). The effect of PDT on the tumors as compared to the controls
was proven by means of the Mann-Whitney test and the Wilcoxon
test at a significance of p ! 0.05.
Results
Fluorescence Investigation
A typical fluorescence spectrum showing its prominent
emission band at Ï G635 nm and Ï G705 nm is depicted
in the inset of figure 1, indicating the evidence for the
detection of PPIX. The fluorescence intensity kinetic due
to the main peak at Ï G635 nm of 5-ALA-induced PPIX
exemplified on one single Dunning tumor is represented
in figure 1. After a slow increase in the fluorescence inten-
sity of PPIX within the first 60 min, the formation of
fluorescing PPIX becomes faster to reach a maximum flu-
orescence intensity between 3 and 4 h post-injection of
5-ALA. Afterwards, fluorescence decreased, indicating
the clearance of PPIX from the tumor tissue, where 8 h
post-5-ALA application only a weak fluorescence could be
measured within the tumor tissue. In all experiments (n =
7) performed, the time range to reach the maximum PPIX
fluorescence intensities was found to be between 3 and
4.5 h post-injection of 5-ALA.
The localization of the PPIX fluorescence is demon-
strated in the fluorescence pattern of a frozen section and
its corresponding HE-stained section in figure 2a, b. The
origin of the red PPIX fluorescence can be attributed
explicitly to the tumor cells, while green autofluorescence
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Fig. 2. Fluorescence pattern (a) of the frozen
section (overview and 10! magnifications)
and the corresponding HE-stained slide (b)
of a Dunning R3327 tumor (overview and
500! magnification). The red PPIX fluores-
cence (a) can be attributed explicitly to the
tumor cells while green autofluorescence is
obtained from adjacent normal connective
subcutaneous tissue.
is obtained from adjacent normal connective subcuta-
neous tissue.
Photodynamic Therapy
The PDT was well tolerated from each animal, espe-
cially no cutaneous photosensitization was observed after
application of 5-ALA. The gross inspection of the tumor
growth measured by calipers at the time of tumor resec-
tion showed an increase of the tumor diameter by a factor
of 2.5 in case of the controls (groups I–III), while the
tumors of the PDT-treated group (IV) were of edematous
and viscid consistence with an increase of macroscopic
growth (p = 0.004) (table 1).
The histopathological investigation showed spheroidal
tumors with an outer layer of vital cells (layer thickness of
Table 1. Macroscopic tumor growth before and after PDT (controls:
6 animals, which received neither 5-ALA nor light)
Group Tumor volume
before PDT
mm3
Tumor volume
after PDT
mm3
Change
PDT Average 82.17 52.41 –416%*
(n = 18) Range 18–224 12–168
Controls Average 41.33 116.50 +226.6%#
(n = 6) Range 12–70 28–200
* p = 0.004; # p = 0.028.
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Fig. 3. a Histopathologic slide of a 90% necrosis of the Dunning
R3327 tumor. HE-stained overview and 50! magnification.
b Enlargement from different zones of the tumor: (A) surrounding
subepidermal stromal tissue with lymphocytic infiltrate; (B) small
zone of vital tumor cells; (C) dark area of mixed apoptosis and necro-
sis, and (D) central apoptotic cells.
Table 2. List of induced necrosis with respect to each treatment
group
Groups Animals Irradiation
J/cm2
5-ALA
mg/kg b.w.
Part of necrosis, %
average B SD range
I 6 0 0 6B4 0–10
II 3 0 150 8B3 0–10
III 3 100 0 7B4 0–10
IV 18 100 150 94B12 60–100
Group I: neither 5-ALA nor light; group II: only 5-ALA no light;
group III: only light no 5-ALA; group IV: PDT.
2–7 cells) which are demonstrated in figure 3. The center
of the tumor mainly shows necrosis and typically includes
a distinct zone of apoptosis close to the vital cell layers, as
seen by a circular accumulation of apoptotic bodies adja-
cent to the necrosis zone in cross sections. In contrast, all
tumors of the control groups showed exclusively vital cells
with insular nests of intratumoral necrosis (!0.5 mm).
The results of the histopathologic quantification of the
necrotic part of the tumors with respect to the treatment
protocol are listed in table 2. The part of the necrosis in
the PDT-treated tumors was calculated to be in an aver-
age of 94 B 12% ranging from 60% up to 100%, while the
controls presented necrosis of maximum 10% (average:
6% group I; 8% group II; 7% group III) 2 days after the
procedure took place. While the percentage of necrosis
differed significantly from the controls (p ! 0.01), no sig-
nificant difference could be calculated from the three con-
trol groups.
Discussion
So far, only a few experimental and clinical studies
have investigated the effective potential of PDT as a treat-
ment modality of PCA. In the early 1980s, McPhee et al.
[16] and Gonzalez et al. [15] demonstrated the efficacy of
PDT using HPD in the Dunning tumor model. In addi-
tion, Henry and Isaacs [17] showed that the combination
of an alkylating chemotherapeutic agent like RSU-1164
and PDT using HPD synergistically produced a greater
retardation in the growth of Dunning tumors in Copenha-
gen rats. In 1990, Windahl et al. [5] reported on 2 patients
with PCA treated by transurethral PDT by means of
HPD. Nevertheless, HPD and Photofrin have two main
limitations [18], i.e. (1) they have a weak light absorption
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at wavelength above 600 nm, while light at longer wave-
lengths penetrates farther into tissue, and (2) they cause
prolonged cutaneous photosensitivity. These properties
provided incentives for developing new photosensitizers.
Recently, Nathan et al. [19] treated 14 patients with local
recurrence of PCA after radiotherapy by PDT using
meso-tetra-m-hydroxyphenyl-chlorin (mTHPC) as a sal-
vage treatment. They concluded that PDT using this
agent might be a new therapeutic option that could be
suitable for organ-confined PCA. Currently, further pho-
tosensitizers or precursors, like 5-ALA, are under inten-
sive experimental and clinical investigation. 5-ALA does
have several advantages – it has a high selectivity in rapid-
ly proliferating cells, it is rapidly eliminated from the
body (within 24 h), it is well tolerated without cutaneous
photosensitization and it can be applied repeatedly with-
out cumulative toxicity [20]. Therefore, PDT using 5-
ALA, with its selective destruction of target tissues could
be an alternative in the treatment of localized PCA. In
vitro experiments by Chakrabarti et al. [21], using two dif-
ferent PCA cell lines (LNCaP, PC-3) showed that 5-ALA-
mediated PDT might be effective in killing PCA cells.
Recently, we demonstrated a significant non-thermal ne-
crosis in the edematous tissue of normal canine prostates
following 5-ALA-mediated PDT. The necrosis was strict-
ly limited to the epithelial tissue compared to the normal
stroma tissue [22]. These findings were consistent with
the results of Johnson et al. [23], who reported about sig-
nificant necrosis in normal canine prostates after PDT
with 5-ALA, compared to unsensitized animals, too.
These promising data provided the background for the
present study to prove the effect of a 5-ALA-mediated
PDT using a variant of the Dunning R3227 tumor in
vivo. This adenocarcinoma was chosen because of its
close similarities with human PCA with regard to its
behavior under hormonal therapy, chemotherapy and
radiation therapy [24]. Recently, Lein et al. [25] demon-
strated that orthotopic implantation of tumor cells may be
needed for accurate assessment of the metastatic poten-
tial. However, the present study evaluates the efficacy of
local tumor control and not of metastatic potential.
Therefore, with regard for accessibility to experimental
manipulation of the PDT, we decided to prove the
selective local tumor destroying effect of 5-ALA-mediated
PDT in a heterotopic model. Nevertheless, this might be a
drawback of the study. Due to the heterotopic approach,
we were not able to study PDT effects on the benign pros-
tate or the adjacent tissue. However, recently, we evaluat-
ed the potential of 5-ALA-mediated PDT in canine pros-
tates. The necrosis was strictly limited to the epithelial tis-
sue of the prostates and no serious local complications
(rectal ulcer, voiding dysfunction, incontinence) were ob-
served [22].
The in vivo fluorescence investigations in the present
study demonstrated the capability of MatLyLu cells to
metabolize an exogenous supply of 5-ALA into PPIX
which is indicated by the suitable PPIX emission spec-
trum. Since an intravenous injection was applied, the flu-
orescence pattern of the frozen section circumstantiates
the assumption of an increased activity of the heme bio-
synthetic pathway in this PCA cell line compared to the
surrounding tissue. This results in a transient and se-
lective accumulation of the photosensitizer PPIX in the
MatLyLu tumor with maximum fluorescence intensity
within 3–4.5 h post-injection. The pharmacokinetic is
comparable to results determined in several other organs
in which 5-ALA-mediated PDT is under clinical investi-
gation [26].
Following PDT, the histological inspection of the tu-
mors resulted in a response of an average of 94% de-
stroyed tumor tissue. In some cases a shell consisting of
2–7 layers of vital cells demarcated the MatLyLu tumor
from the adjacent normal tissue. These cells most likely
proliferated after PDT had been performed, since the cells
are adjacent to the supplying vasculature. Several factors
might account for the differences in the extent of the cell
damage observed after PDT, e.g. photosensitizer concen-
tration, irradiation, oxygen. However, the present study
was not designed to perform a dose-response investiga-
tion examining the impact of various 5-ALA concentra-
tions, or different light doses. Further studies will asses
these variables.
In the inner part of the spheroidal tumors, necrotic as
well apoptotic cells could be observed. While the necroses
were the result of immediate PDT cell killing due to an
optimum combination of PPIX concentration, optimum
light excitation and sufficient intracellular oxygen sup-
port, it could be assumed that the apoptotic cells were the
result of insufficient PDT most likely due to hypoxia and
a lower PPIX concentration [27, 28].
The results demonstrate a high effectiveness of 5-ALA-
mediated PDT in the Dunning R3327 prostate adenocar-
cinoma. With regard to the macroscopic and microscopic
findings, the effects of PDT differed significantly from the
controls which exhibited only a low rate of spontaneous
necrosis. The comparison of the macroscopic measure-
ments of the tumor sizes by calipers pre-PDT and pre-
tumor resection showed effective tissue reaction due to
PDT while the tissue growth of the controls progressed
continuously.
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Conclusion
In conclusion, this study suggests that the injection of
exogenous 5-ALA induced a selective PPIX accumulation
in this in vivo tumor model. Performing PDT after the
determined incubation time results in effective killing of
PCA in the Dunning R3327 tumor model when suitable
parameters are used.
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